Option Care Health Inc. Common Stock (OPCH)
Stock · NASDAQ · Health Care
$31.2as of 10/16/2026
Price chart
Active signals
OPCH Signal Track Record
How signals performed across all stocks →What OPCH's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | +2.1% | 59% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 26 | +0.8% | 58% | March 4, 2026 |
| Bollinger Band Breakdown | 19 | +1.2% | 63% | September 24, 2026 |
| Bollinger Band Breakout | 18 | +0.3% | 50% | October 6, 2026 |
| Any 20-session window (baseline) | -0.0% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About OPCH
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of i…
- Sector
- Health Care
- Industry
- Medical/Nursing Services
- Employees
- 8,000
- Website
- optioncarehealth.com/
Fundamentals
- 1-day range
- $22.45$23.24
- Market cap
- $3.54B
- P/E (trailing)
- 22.23
- P/E (forward)
- 11.15
- EPS (trailing)
- $1.32
- Dividend yield
- —
- Beta
- 0.52
- Avg. volume
- 2.18M
- Dividend pay date
- February 3, 2020
How Option Care Health Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Option Care Health Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- OPCHOption Care Health Inc. Common Stock$31.2▼ 0.06%Market cap $3.54BP/E 22.23$18.01$36.8
- LFSTLifeStance Health Group Inc. Common Stock$11.74▼ 5.09%Market cap $4.13BP/E 93.42$4.77$13.56
- PRVAPrivia Health Group Inc. Common Stock$22.52▼ 0.44%Market cap $2.77BP/E 102.74$18.92$28.82
- ADUSAddus HomeCare Corporation Common Stock$115.98▼ 0.44%Market cap $2.22BP/E 20.70$87.95$124.44
- WGSGeneDx Holdings Corp. Class A Common Stock$63.61▼ 9.41%Market cap $2.08BP/E —$32.21$170.87
- AVAHAveanna Healthcare Holdings Inc. Common Stock$12.34▼ 2.37%Market cap $2.03BP/E 10.04$5.93$14.71
- INNVInnovAge Holding Corp. Common Stock$8.85▼ 1.45%Market cap $1.49BP/E —$3.94$12.64
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OPCH Option Care Health Inc. Common Stock | $3.54B | 22.23 | $31.2 | ▼ 0.06% | $18.01$36.8 |
| LFST LifeStance Health Group Inc. Common Stock | $4.13B | 93.42 | $11.74 | ▼ 5.09% | $4.77$13.56 |
| PRVA Privia Health Group Inc. Common Stock | $2.77B | 102.74 | $22.52 | ▼ 0.44% | $18.92$28.82 |
| ADUS Addus HomeCare Corporation Common Stock | $2.22B | 20.70 | $115.98 | ▼ 0.44% | $87.95$124.44 |
| WGS GeneDx Holdings Corp. Class A Common Stock | $2.08B | — | $63.61 | ▼ 9.41% | $32.21$170.87 |
| AVAH Aveanna Healthcare Holdings Inc. Common Stock | $2.03B | 10.04 | $12.34 | ▼ 2.37% | $5.93$14.71 |
| INNV InnovAge Holding Corp. Common Stock | $1.49B | — | $8.85 | ▼ 1.45% | $3.94$12.64 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 2 Profitable Stocks on Our Buy List and 1 We Find RiskyYahoo · 10/1/2026
- BTSG Deploys AI Across Operations: Will It Improve Margins?Yahoo · 9/30/2026
- Option Care Health (OPCH) Draws Fresh Home Care Attention, Is It Still 20% Undervalued?Yahoo · 9/30/2026
- Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?Yahoo · 9/30/2026
- BrightSpring vs. Option Care Health: Which Healthcare Stock Is Better?Yahoo · 9/29/2026
- Are Investors Undervaluing Aveanna Healthcare (AVAH) Right Now?Yahoo · 9/24/2026
- 3 Healthcare Stocks with Warning SignsYahoo · 9/23/2026
- 3 Reasons to Sell OPCH and 1 Stock to Buy InsteadYahoo · 9/22/2026
Insider Activity
Insider Actions →- Prateek Bhatia · July 6, 2026 · Grant23.4K
- Prateek Bhatia · July 6, 2026 · Grant16.4K
- Elizabeth D. Bierbower · May 20, 2026 · Grant9.0K
- Natasha Deckmann · May 20, 2026 · Grant844 @ $22.23
- Natasha Deckmann · May 20, 2026 · Grant9.0K
- Harry M. Jansen Kraemer Jr. · May 20, 2026 · Grant12.1K @ $22.23
- Norman L. Wright · May 20, 2026 · Grant9.0K
- Eric Brandt · May 20, 2026 · Grant2.6K @ $22.23
- Eric Brandt · May 20, 2026 · Grant9.0K
- Harry M. Jansen Kraemer Jr. · May 20, 2026 · Grant9.0K
- R. Carter Pate · May 20, 2026 · Grant9.0K
- Timothy P. Sullivan · May 20, 2026 · Grant4.8K @ $22.23
- Timothy P. Sullivan · May 20, 2026 · Grant9.0K
- Barbara W. Bodem · May 20, 2026 · Grant9.0K
- Collin Smyser · May 19, 2026 · Option Exercise812
Institutional Ownership
March 31, 2026
- Total shares held
- 155.69M
- Total value held
- $4.03B
- Institutional holders
- 361
- Unknown19.89M
- Unknown11.90M
- Unknown8.99M
- Unknown7.13M
- Unknown7.02M
- Unknown6.43M
- Unknown5.87M
- Unknown4.45M
- Unknown4.25M
- Unknown4.24M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
McKesson moves to acquire Option Care Health in $5.8B deal
Option Care Health is the target of a $5.8 billion acquisition by McKesson, which has lifted the stock in recent trading. The deal is under legal review, and several analysts have lowered their ratings, with UBS moving to neutral and William Blair to market‑perform. The mixed reactions reflect both the premium offered and the uncertainties around regulatory approval.
McKesson moves to acquire Option Care Health in $5.8B deal. Option Care Health is the target of a $5.8 billion acquisition by McKesson, which has lifted the stock in recent trading. The deal is under legal review, and several analysts have lowered their ratings, with UBS moving to neutral and William Blair to market‑perform. The mixed reactions reflect both the premium offered and the uncertainties around regulatory approval.